Cargando…
The deacetylation of Foxk2 by Sirt1 reduces chemosensitivity to cisplatin
In multiple types of cancer, decreased tumour cell apoptosis during chemotherapy is indicative of decreased chemosensitivity. Forkhead box K2 (FOXK2), which is essential for cell fate, regulates cancer cell apoptosis through several post‐translational modifications. However, FOXK2 acetylation has no...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743664/ https://www.ncbi.nlm.nih.gov/pubmed/34866322 http://dx.doi.org/10.1111/jcmm.17107 |
_version_ | 1784629954488565760 |
---|---|
author | Wang, Xi‐wen Guo, Qi‐qiang Yu, Yang Zhou, Ting‐ting Zhang, Si‐yi Wang, Zhuo Liu, Jing‐wei Tang, Jun Jiang, Xiao‐you Wang, Shan‐shan Guo, Wen‐dong Xu, Hong‐de Sun, Hua‐yi Li, Zi‐wei Song, Xiao‐yu Zhao, Jun‐gang Cao, Liu |
author_facet | Wang, Xi‐wen Guo, Qi‐qiang Yu, Yang Zhou, Ting‐ting Zhang, Si‐yi Wang, Zhuo Liu, Jing‐wei Tang, Jun Jiang, Xiao‐you Wang, Shan‐shan Guo, Wen‐dong Xu, Hong‐de Sun, Hua‐yi Li, Zi‐wei Song, Xiao‐yu Zhao, Jun‐gang Cao, Liu |
author_sort | Wang, Xi‐wen |
collection | PubMed |
description | In multiple types of cancer, decreased tumour cell apoptosis during chemotherapy is indicative of decreased chemosensitivity. Forkhead box K2 (FOXK2), which is essential for cell fate, regulates cancer cell apoptosis through several post‐translational modifications. However, FOXK2 acetylation has not been extensively studied. Here, we evaluated the effects of sirtiun 1 (SIRT1) on FOXK2 deacetylation. Our findings demonstrated that SIRT1 inhibition increased FOXK2‐induced chemosensitivity to cisplatin and that K223 in FOXK2 was acetylated. Furthermore, FOXK2 K223 deacetylation reduced chemosensitivity to cisplatin in vitro and in vivo. Mechanistically, FOXK2 was acetylated by the acetyltransferase cAMP response element binding protein and deacetylated by SIRT1. Furthermore, cisplatin attenuated the interaction between FOXK2 and SIRT1. Cisplatin or SIRT1 inhibition enhanced FOXK2 acetylation, thereby reducing the nuclear distribution of FOXK2. Additionally, FOXK2 K223 acetylation significantly affected the expression of cell cycle–related and apoptosis‐related genes in cisplatin‐stimulated cancer cells, and FOXK2 K223 hyperacetylation promoted mitotic catastrophe, which enhanced chemosensitivity to cisplatin. Overall, our results provided insights into the mechanisms of SIRT1‐mediated FOXK2 deacetylation, which was involved in chemosensitivity to cisplatin. |
format | Online Article Text |
id | pubmed-8743664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87436642022-01-12 The deacetylation of Foxk2 by Sirt1 reduces chemosensitivity to cisplatin Wang, Xi‐wen Guo, Qi‐qiang Yu, Yang Zhou, Ting‐ting Zhang, Si‐yi Wang, Zhuo Liu, Jing‐wei Tang, Jun Jiang, Xiao‐you Wang, Shan‐shan Guo, Wen‐dong Xu, Hong‐de Sun, Hua‐yi Li, Zi‐wei Song, Xiao‐yu Zhao, Jun‐gang Cao, Liu J Cell Mol Med Original Articles In multiple types of cancer, decreased tumour cell apoptosis during chemotherapy is indicative of decreased chemosensitivity. Forkhead box K2 (FOXK2), which is essential for cell fate, regulates cancer cell apoptosis through several post‐translational modifications. However, FOXK2 acetylation has not been extensively studied. Here, we evaluated the effects of sirtiun 1 (SIRT1) on FOXK2 deacetylation. Our findings demonstrated that SIRT1 inhibition increased FOXK2‐induced chemosensitivity to cisplatin and that K223 in FOXK2 was acetylated. Furthermore, FOXK2 K223 deacetylation reduced chemosensitivity to cisplatin in vitro and in vivo. Mechanistically, FOXK2 was acetylated by the acetyltransferase cAMP response element binding protein and deacetylated by SIRT1. Furthermore, cisplatin attenuated the interaction between FOXK2 and SIRT1. Cisplatin or SIRT1 inhibition enhanced FOXK2 acetylation, thereby reducing the nuclear distribution of FOXK2. Additionally, FOXK2 K223 acetylation significantly affected the expression of cell cycle–related and apoptosis‐related genes in cisplatin‐stimulated cancer cells, and FOXK2 K223 hyperacetylation promoted mitotic catastrophe, which enhanced chemosensitivity to cisplatin. Overall, our results provided insights into the mechanisms of SIRT1‐mediated FOXK2 deacetylation, which was involved in chemosensitivity to cisplatin. John Wiley and Sons Inc. 2021-12-06 2022-01 /pmc/articles/PMC8743664/ /pubmed/34866322 http://dx.doi.org/10.1111/jcmm.17107 Text en © 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Wang, Xi‐wen Guo, Qi‐qiang Yu, Yang Zhou, Ting‐ting Zhang, Si‐yi Wang, Zhuo Liu, Jing‐wei Tang, Jun Jiang, Xiao‐you Wang, Shan‐shan Guo, Wen‐dong Xu, Hong‐de Sun, Hua‐yi Li, Zi‐wei Song, Xiao‐yu Zhao, Jun‐gang Cao, Liu The deacetylation of Foxk2 by Sirt1 reduces chemosensitivity to cisplatin |
title | The deacetylation of Foxk2 by Sirt1 reduces chemosensitivity to cisplatin |
title_full | The deacetylation of Foxk2 by Sirt1 reduces chemosensitivity to cisplatin |
title_fullStr | The deacetylation of Foxk2 by Sirt1 reduces chemosensitivity to cisplatin |
title_full_unstemmed | The deacetylation of Foxk2 by Sirt1 reduces chemosensitivity to cisplatin |
title_short | The deacetylation of Foxk2 by Sirt1 reduces chemosensitivity to cisplatin |
title_sort | deacetylation of foxk2 by sirt1 reduces chemosensitivity to cisplatin |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743664/ https://www.ncbi.nlm.nih.gov/pubmed/34866322 http://dx.doi.org/10.1111/jcmm.17107 |
work_keys_str_mv | AT wangxiwen thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT guoqiqiang thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT yuyang thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT zhoutingting thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT zhangsiyi thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT wangzhuo thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT liujingwei thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT tangjun thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT jiangxiaoyou thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT wangshanshan thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT guowendong thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT xuhongde thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT sunhuayi thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT liziwei thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT songxiaoyu thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT zhaojungang thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT caoliu thedeacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT wangxiwen deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT guoqiqiang deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT yuyang deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT zhoutingting deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT zhangsiyi deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT wangzhuo deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT liujingwei deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT tangjun deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT jiangxiaoyou deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT wangshanshan deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT guowendong deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT xuhongde deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT sunhuayi deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT liziwei deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT songxiaoyu deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT zhaojungang deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin AT caoliu deacetylationoffoxk2bysirt1reduceschemosensitivitytocisplatin |